|
|
(14 intermediate revisions by 2 users not shown) |
Line 1: |
Line 1: |
| {{familytree/start}} | | {{familytree/start}} |
| {{familytree | | | | | | | | A01 | | | | | | | | |A01=Newly discovered [[AF]] }} | | {{familytree | | | | | | | | | | | | A01 | | |A01=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Characterize the symptoms:'''<br> |
| {{familytree | | | |,|-|-|-|-|^|-|-|-|-|.| | | | | }} | | ❑ Cardiac |
| {{familytree | | | B01 | | | | | | | | B02 | | | |B01=Paroxysmal|B02=Persistent }}
| | :❑ '''Chest pain described as <br>tearing, ripping, sharp or stabbing<sup>*</sup>''' |
| {{familytree | | | |!| | | | | | | | | | | | | | | }} | | :❑ '''Abrupt onset of pain and <br>increasing in intensity<sup>*</sup>''' |
| {{familytree | | | C01 | | | | | C02 | | | | C03 | |C01=Look for the presence of one of these severe symptoms <br> Hypotension <br> Heart failure <br> Angina pectoris
| | :❑ Chest pain worsened by deep breathing or cough and <br> relieved by sitting upright |
| ----
| | :❑ [[Anxiety]] |
| Severe symptoms absent: <br> No therapy needed
| | :❑ [[Palpitation]] |
| ----
| | :❑ Fainting |
| Severe symptoms present:
| | :❑ Sweating |
| Attempt direct-current cardioversion| C02=Permanent AF |C03=Anticoagulation as needed based on the risk of stroke <br> Click [[Atrial fibrillation resident survival guide#Risk Factors for Stroke and Recommended Antithrombotic Therapy|here]] for the risk of stroke and anticoagulation therapy
| | :❑ Pale skin |
| ----
| | :❑ Rapid, weak pulse |
| Control heart rate as an intial method to terminate AF <br> Click here for recommended pharmacological agents used for rate control }}
| | :❑ Shortness of breath |
| {{familytree | | | |!| | | | | | | | | | | | | | | }}
| | :❑ [[Peripheral edema]] |
| {{familytree | | | D01 | | | | | D02 | | | | D03 | |D01=Anticoagulation as needed based on the risk of stroke <br> Click [[Atrial fibrillation resident survival guide#Risk Factors for Stroke and Recommended Antithrombotic Therapy|here]] for the risk of stroke and anticoagulation therapy
| | :❑ Rapid breathing |
| ----
| | :❑ [[Orthopnea]] |
| Recommended in all cases except lone AF (I A) <br> Measure INR weekly initially, then monthly when stable (I A) <br> Reassess need for anticoagulation at periodic intervals (IIa C)|D02=Anticoagulation as needed based on the risk of stroke <br> Click [[Atrial fibrillation resident survival guide#Risk Factors for Stroke and Recommended Antithrombotic Therapy|here]] for the risk of stroke and anticoagulation therapy
| | ❑ Extra cardiac |
| ----
| | :❑ [[Abdominal pain]] or [[back pain]] |
| Control heart rate as an intial method to terminate AF <br> Click here for recommended pharmacological agents used for rate control| D03= }}
| | :❑ [[Flank pain]] |
| {{familytree | | | | | | | | | | | | | | | | | | | }} | | :❑ Lower and upper extremity weakness, numbness and tingling |
| {{familytree | | | | | | | | | | | | | | | | | | | }}
| | :❑ Nausea and vomiting |
| {{familytree | | | | | | | | | | | | | | | | | | | }} | | :❑ Symptoms suggestive of [[stroke]] |
| {{familytree | | | | | | | | | | | | | | | | | | | }}
| | :❑ Swallowing difficulties due to pressure on the esophagus |
| {{familytree | | | | | | | | | | | | | | | | | | | }}
| | :❑ [[Gastrointestinal bleeding]] |
| {{familytree/end}}
| | :❑ [[Altered mental status]] |
| | :❑ Feeling of impending doom |
| | :❑ [[Hemoptysis]] |
| | :❑ [[Ptosis (eyelid)|Drooping of eyelids]] |
| | :❑ Decreased or no sweating |
| | :❑ [[Haematemesis]] |
| | :❑ [[Laryngitis|Hoarseness of voice]]</div>}} |
| | {{ familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | }} |
| | {{ familytree | | | | | | | | | | | | B01 | | | | | | | | | | | |B01=<div style="float: left; text-align: left; width: 20em; padding:1em;"> |
| | '''Obtain a detailed history:'''<br> |
| | ❑ Past medical history |
| | :❑ [[Hypertension]] |
| | :❑ [[Pheochromocytoma ]] |
| | ❑ Family history |
| | :❑ '''Aortic disorder<sup>*</sup>''' |
| | :❑ '''[[Connective tissue disorder]]<sup>*</sup>''' |
| | ❑ Anatomic deformities |
| | :❑ '''Aortic valve disease<sup>*</sup>''' |
| | :❑ '''[[Thoracic aortic aneurysm]]<sup>*</sup>''' |
| | :❑ [[Coarctation of aorta]] |
| | :❑ [[Polycystic kidney disease]] |
| | ❑ Iatrogenic |
| | :❑ '''Recent aortic manipulation<sup>*</sup>''' |
| | :❑ Chronic steroid usage |
| | :❑ Immunosuppressive therapy |
| | ❑ Lifestyle |
| | :❑ [[Cocaine]] abuse |
| | :❑ Heavy weight lifting |
| | ❑ Trauma<br> |
| | ❑ Genetic |
| | :❑ '''[[Marfan's syndrome]]<sup>*</sup>''' |
| | :❑ [[Ehlers-Danlos syndrome]] |
| | :❑ [[Turners syndrome]] |
| | :❑ [[Bicuspid aortic stenosis|Biscuspid aortic valve]] |
| | :❑ [[Loeys-Dietz syndrome]] |
| | :❑ Familial thoracic aneurysm and dissection syndrome |
| | ❑ Inflammatory vasculitis |
| | :❑ [[Takayasu arteritis]] |
| | :❑ [[Giant cell arteritis]] |
| | :❑ [[Behcet's disease|Behcet's arteritis]] |
| | ❑ Pregnancy |
| | ❑ Infections involving the aorta </div>}} |
| | {{ familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | }} |
| | {{ familytree | | | | | | | | | | | | C01 | | | | | | | | | | | |C01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Examine the patient:'''<br> |
| | ❑ General examination: |
| | :❑ Pulse rate - ↑ |
| | :❑ Blood pressure - ↑ or ↓ |
| | :❑ Respiratory rate - ↑ |
| | :❑ [[Wide pulse pressure]] |
| | :❑ '''Difference in the blood pressure in both extremities<sup>*</sup>''' |
| | :❑ '''Signs of [[shock]] (hypoperfusion)<sup>*</sup>''' |
| | :❑ '''Pulse deficit involving carotid, femoral or subclavian arteries<sup>*</sup>''' |
| | :❑ Increased sweating or [[anhidrosis]] |
|
| |
|
| ==Antiarrhythmic Drug Therapy in Atrial Fibrillation==
| | ❑ Head/neck examination: |
| Shown below is an algorithm depicting the antiarrhythmic drug therapy for maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation:
| | :❑ ↑ JVP |
| | | :❑ Signs of vocal cord paralysis |
| {{familytree/start |summary=PE diagnosis Algorithm.}}
| | :❑ [[Pemberton's sign]] (SVC) |
| {{familytree| | | | | | | | | | | | | | | A01 | | | | | | A01=Maintenance of [[sinus rhythm]]}}
| | :❑ Venous distention in the neck and distended veins in the upper chest and arms (SVC) |
| {{familytree| | | |,|-|-|-|-|-|-|-|v|-|-|-|^|-|-|-|v|-|-|-|-|-|.| | }}
| | ❑ Cardiovascular examination: |
| {{familytree| | | B01 | | | | | | B02 | | | | | | B03 | | | | B04 | B01=No (or minimal) heart disease| B02=[[Hypertension]]| B03=[[Coronary artery disease]]| B04=[[Heart failure]]}}
| | :❑ '''[[Diastolic murmur]] suggestive of [[aortic regurgitation]]<sup>*</sup>''' |
| {{familytree| | | |!| | | | | | | |!| | | | | | | |!| | | | | |!| | | | | |}}
| | :❑ [[Wheeze]] (cardiac asthma) (CHF) |
| {{familytree| | | C01 | | | | | | C02 | | | | | | C03 | | | | C04 | | | | C01=[[Dronedarone]] <br> [[Flecainide]]<br>[[Propafenone]]<br>[[Sotalol]]| C02=Substantial [[LVH]]|C03=[[Dronedarone]] <br>[[Dofetilide]]<br>[[Sotalol]]|C04=[[Amiodarone]]<br>[[Dofetilide]]}} | | :❑ [[Pericardial friction rub]] |
| {{familytree| |,|-|^|-|.| | | |,|-|^|-|.| | | |,|-|^|-|.| | | |!| | | | | | |}}
| | ❑ Respiratory examination |
| {{familytree| D01 | | D02 | | D03 | | D04 | | D05 | | D06 | | D07 | | | | | | ||D01=[[Amiodarone]]<br>[[Dofetilide]]|D02=[[Catheter ablation]]|D03=No|D04=Yes|D05=[[Amiodarone]]|D06=[[Catheter ablation]]|D07=[[Catheter ablation]]}} | | :❑ [[Crackles]] / [[crepitations]] / [[rales]] |
| {{familytree| | | | | | | | | |!| | | |!| | | | | | | |}}
| | :❑ Decreased movement of the chest on affected side |
| {{familytree| | | | | | | | | E01 | | E02 | | | | | E01=[[Dronedarone]] <br> [[Flecainide]]<br>[[Propafenone]]<br>[[Sotalol]]|E02=[[Amiodarone]]}}
| | :❑ Stony dullness to percussion |
| {{familytree| | | | | | | | | |!| | | |!| | | | | | | |}}
| | :❑ Diminished breaths sounds |
| {{familytree| | | | | | | | | |!| | | F03 | | | | | | |F03=[[Catheter ablation]]}}
| | :❑ Decreased [[vocal fremitus]] |
| {{familytree| | | | | | | |,|-|^|-|.| | | | | | | | | | | | | | }}
| | :❑ [[Pleural friction rub]]. |
| {{familytree| | | | | | | F01 | | F02 | | | | | | | | | F01=[[Amiodarone]]<br>[[Dofetilide]]|F02=[[Catheter ablation]]}}
| | ❑ Abdominal examination: |
| {{familytree/end}} | | :❑ [[Ascites]] |
| Drugs are listed alphabetically and not in order of suggested use. <br>The seriousness of heart disease progresses from left to right, and selection of therapy in patients with multiple conditions depends on the most serious condition present.<br> LVH indicates left ventricular hypertrophy.<br>
| | :❑ [[Claudication]] of buttocks |
| ''Algorithm based on the 20011 ACCF/AHA/HRS updates for the management of atrial fibrillation.''<ref name="Fuster-2011">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref> | | :❑ Absent femoral pulses |
| | | ❑ Neurological examination: |
| ==Pharmacological Cardioversion== | | :❑ '''[[Altered mental status]]<sup>*</sup>''' |
| | | :❑ Signs of [[peripheral neuropathy]] |
| ===Cardioversion upto7 Days===
| | :❑ '''Signs suggestive of [[stroke]]<sup>*</sup>''' |
| | | ❑ Extremity examination: |
| <table class="wikitable">
| | :❑ [[Edema|Pedal edema]] |
| <tr class="v-firstrow"><th>Drug</th><th>Class of Recommendation/<br>Level of Evidence</th><th> Dosage </th></tr>
| | ❑ Ophthalmological examination |
| <tr><th>Agents with proven efficacy</th></tr>
| | :❑ [[Miosis]] |
| <tr><td>Dofetilide</td><td>I A</td><td><table class="wikitable">
| | :❑ [[Ptosis]] </div>}} |
| <tr class="v-firstrow"><th>Creatinine clearance(ml/min)</th><th>Dose (mg)</th></tr>
| | {{ familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | }} |
| <tr><td> >60</td><td>500</td></tr>
| | {{ familytree | | | | | | | | | | | | D01 | | | | | | | | | | | |D01=<div style="float: left; text-align: left; width: 25em; padding:1em;">❑ Assess the severity by counting the high risk features marked in '''bold''' and by * </div>}} |
| <tr><td> 40 to 60 </td><td>250 </td></tr>
| | {{ familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | }} |
| <tr><td>20 to 40 </td><td>125 </td></tr>
| | {{ familytree | | | | | | | | | | | | E01 | | | | | | | | | | | |E01=<div style="float: left; text-align: left; width: 25em; padding:1em;">❑ Consider close differential diagnoses: |
| <tr><td> <20</td><td>Contraindicated</td></tr>
| | :❑ [[Aortic regurgitation]] |
| </table></td></tr>
| | :❑ [[Aortic stenosis]] |
| <tr><td>Flecainide</td><td> I A</td><td>'''Oral:''' 200 to 300 mg <br>
| | :❑ [[Aortic aneurysm]] |
| '''Intravenous:''' 1.5 to 3.0 mg/kg over 10 to 20 min</td></tr>
| | :❑ [[Atherosclerosis|Atherosclerotic]] or [[Cholesterol emboli syndrome|cholesterol embolism]] |
| <tr><td>Ibutilide</td><td>I A </td><td>1 mg over 10 min; repeat 1 mg when necessary</td></tr>
| | :❑ [[Cardiac tamponade]] |
| <tr><td>Propafenone</td><td>I A</td><td>'''Oral:''' 600 mg <br>
| | :❑ [[Cardiogenic shock]] |
| '''Intravenous:''' 1.5 to 2.0 mg/kg over 10 to 20 min</td></tr>
| | :❑ [[Cholecystitis]] |
| <tr><td>Amiodarone</td><td>IIa A</td><td>'''Oral:'''
| | :❑ [[Esophageal perforation]] rupture |
| : Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total <br> then 200 to 400 mg per day maintenance or 30 mg/kg as single dose <br>
| | :❑ [[Gastroenteritis]] |
| : Outpatient: 600 to 800 mg per day divided dose until 10 g total <br> then 200 to 400 mg per day maintenance. <br>
| | :❑ [[Hemorrhagic shock]] |
| '''Intravenous:'''
| | :❑ [[Hernias]] |
| : 5 to 7 mg/kg over 30 to 60 min then 1.2 to 1.8 g per day continuous IV or <br>
| | :❑ [[Hypertensive emergencies]] |
| : in divided oral doses until 10 g total then 200 to 400 mg per day maintenance.</td></tr>
| | :❑ [[Hypovolemic shock]] |
| </table>
| | :❑ [[Myalgia|Musculoskeletal pain]] |
| | | :❑ [[Mediastinal tumors]] |
| ===Cardioversion after 7 Days===
| | :❑ [[Myocardial infarction]] |
| | | :❑ [[Myocarditis]] |
| <table class="wikitable">
| | :❑ [[Myopathies]] |
| <tr class="v-firstrow"><th>Drug</th><th> Dosage </th></tr><tr><td>Dofetilide (I A)</td><td><table class="wikitable">
| | :❑ [[Pancreatitis]] |
| <tr class="v-firstrow"><th>Creatinine clearance(ml/min)</th><th>Dose (mg)</th></tr>
| | :❑ [[Pericarditis]] |
| <tr><td> >60</td><td>500</td></tr>
| | :❑ [[Pleuritis]] |
| <tr><td> 40 to 60 </td><td>250 </td></tr>
| | :❑ [[Peptic ulcer disease]] or perforating ulcer |
| <tr><td>20 to 40 </td><td>125 </td></tr>
| | :❑ [[Peripheral vascular injuries]] |
| <tr><td> <20</td><td>Contraindicated</td></tr>
| | :❑ [[Pleural effusion]] |
| </table></td></tr>
| | :❑ [[Pulmonary embolism]] |
| <tr><td>Amiodarone (IIa A)</td><td>'''Oral:'''
| | :❑ [[Thoracic outlet syndrome]]</div>}} |
| : Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total <br> then 200 to 400 mg per day maintenance or 30 mg/kg as single dose <br>
| | {{ familytree | | | |,|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|.| | | | | }} |
| : Outpatient: 600 to 800 mg per day divided dose until 10 g total <br> then 200 to 400 mg per day maintenance. <br>
| | {{ familytree | | | F01 | | | | | | | F02 | | | | | | F03 | | | |F01='''Low Risk'''<div style="float: left; text-align: left; width: 25em; padding:1em;">❑ No high risk features present<br>❑ Clinical presentation is not initially<br> suggestive for dissection but aortic imaging<br> may help in the absence of alternative diagnosis</div> |F02='''Intermediate Risk'''<br><div style="float: left; text-align: left; width: 25em; padding:1em;">❑ Single high risk present<br>❑ Concerning presentation for acute dissection and requires aortic imaging if no alternate diagnosis can be reached </div>|F03='''High Risk'''<div style="float: left; text-align: left; width: 25em; padding:1em;"> ❑ Two or more high risk features present <br>❑ Acute dissection requiring immediate<br> surgical evaluation and expedited aortic imaging </div>}} |
| '''Intravenous:'''
| | {{ familytree | | | |!| | | | | | | | |!| | | | | | | |!| | | | | }} |
| : 5 to 7 mg/kg over 30 to 60 min then 1.2 to 1.8 g per day continuous IV or <br>
| | {{ familytree | | | G01 | | | | | | | G02 | | | | | | |!| | | | |G01= |G02= }} |
| : in divided oral doses until 10 g total then 200 to 400 mg per day maintenance.</td></tr>
| | {{ familytree | |,|-|^|-|.| | | |,|-|-|^|-|-|.| | | | |!| | | | | }} |
| <tr><td>Ibutilide (IIa A)</td><td>1 mg over 10 min; repeat 1 mg when necessary</td></tr>
| | {{ familytree | H01 | | H02 | | H03 | | | | H04 | | | H05 | | | |H01= |H02= |H03= |H04= |H05= }} |
| </table>
| | {{ familytree | |!| | | |!| | | |!| | | | | |!| | | | |!| | | | | }} |
| | | {{ familytree | I01 | | I02 | | I03 | | | | I04 | | | |!| | | |I01= |I02= |I03= |I04= }} |
| Drugs which enhance the efficacy of cardioversion when given prior to the procedure: (Level of recommendation: IIa B)
| | {{ familytree | | | |,|-|^|-|.| |!| | |,|-|-|^|-|-|.| |!| | | | | }} |
| * Amiodarone
| | {{ familytree | | | J01 | | J02 |!| | J03 | | | | J04 |!| | | | |J01= |J02= |J03= |J04= }} |
| * Flecainide
| | {{ familytree | | | |!| | | |!| |!| | | | | | | | |!| |!| | | | | }} |
| * Ibutilide
| | {{ familytree | | | K01 | | |`|-|`|-| K02 |-|-|-|-|'|-|'| | | | |K01= |K02= }} |
| * Propafenone
| | {{ familytree | | | | | | | | | | | | |!| | | | | | | | | | | }} |
| * Sotalol
| | {{ familytree | | | | | | | | | | | | L01 | | | | | | | | | | | |L01= }} |
| | | {{ familytree | | | | | | | | | | | | |!| | | | | | | | | | | }} |
| ==Risk Factors for Stroke and Recommended Antithrombotic Therapy==
| | {{ familytree | | | | | | | | | | | | M01 | | | | | | | | | | | |M01= }} |
| <table class="wikitable">
| | {{ familytree | | | | | | | | | |,|-|-|^|-|-|.| | | | | | | | }} |
| <tr class="v-firstrow"><th>Low Risk Factors</th><th>Moderate Risk Factors</th><th>High Risk Factors</th></tr>
| | {{ familytree | | | | | | | | | N01 | | | | N02 | | | | | | | |N01= |N02= }} |
| <tr><td>Female gender</td><td>Age ≥ 75 years</td><td>Previous stroke, TIA or embolism </td></tr>
| | {{ familytree | | | | | | | | | |!| | | | | |!| | | | | | | | }} |
| <tr><td>Age 65-74 years</td><td>Hypertension</td><td>Mitral stenosis</td></tr>
| | {{ familytree | | | | | | | | | O01 | | | | O02 | | | | | | | |O01= |O02= }} |
| <tr><td>Coronary artery disease</td><td>Heart failure</td><td>Prosthetic heart valve</td></tr>
| |
| <tr><td>Thyrotoxicosis</td><td>LV ejection fraction ≤ 35%</td><td> - </td></tr>
| |
| <tr><td> - </td><td>Diabetes mellitus</td><td> - </td></tr>
| |
| </table>
| |
| | |
| <table class="wikitable">
| |
| <tr class="v-firstrow"><th>Risk Category</th><th>Recommended Therapy</th></tr>
| |
| <tr><td>No risk factors</td><td>Aspirin, 81-325 mg daily</td></tr>
| |
| <tr><td>1 Moderate risk factor </td><td>Aspirin, 81-325 mg daily or <br> Warfarin (INR 2.0 to 3.0, target 2.5)</td></tr>
| |
| <tr><td>Any high risk factor or <br> more than 1 moderate risk factor</td><td>Warfarin<br> (INR 2.0 to 3.0, target 2.5)*</td></tr>
| |
| </table>
| |
| | |
| ==Pharmacological Agents for Heart Rate Control==
| |
| <table class="wikitable">
| |
| <tr class="v-firstrow"><th>Drug</th><th>Class/LOE <br> Recommendations</th><th>Loading Dose</th><th>Maintenance Dose</th></tr>
| |
| <tr><th>Acute Setting</th></tr>
| |
| <tr><th>Heart rate control in patients without accessory pathway</th></tr>
| |
| <tr><td>Esmolol</td><td>I C</td><td>500 mcg/kg IV over 1 min</td><td>60 to 200 mcg/kg/min IV</td></tr>
| |
| <tr><td>Propanolol</td><td>I C </td><td>0.15 mg/kg IV</td><td>NA</td></tr>
| |
| <tr><td>Metoprolol</td><td>I C </td><td>2.5 to 5 mg IV bolus over 2 min; up to 3 doses</td><td>NA</td></tr>
| |
| <tr><td>Diltiazem</td><td>I B</td><td>0.25 mg/kg IV over 2 min</td><td>5 to 15 mg/h IV</td></tr>
| |
| <tr><td>Verampil</td><td>I B</td><td>0.075 to 0.15 mg/kg IV over 2 min</td><td>NA</td></tr>
| |
| <tr><th>Heart Rate Control in patients with accessory pathway</th></tr>
| |
| <tr><td>Amiodarone</td><td>IIa C</td><td>150 mg over 10 min</td><td>0.5 to 1 mg/min IV</td></tr>
| |
| <tr><th>Heart Rate Control in patients with heart failure and without accessory pathway</th></tr>
| |
| <tr><td>Digoxin</td><td>I B</td><td>0.25 mg IV each 2 h, up to 1.5 mg</td><td>0.125 to 0.375 mg daily IV or orally</td></tr>
| |
| <tr><td>Amiodarone</td><td>IIa C</td><td>150 mg over 10 min</td><td>0.5 to 1 mg/min IV</td></tr>
| |
| <tr><th>Non-Acute Setting and Chronic Maintenance Therapy</th></tr>
| |
| <tr><th>Heart rate control</th></tr>
| |
| <tr><td>Metoprolol</td><td>I C</td><td>Same as maintenance dose</td><td>25 to 100 mg twice a day, orally</td></tr>
| |
| <tr><td>Propanolol</td><td>I C</td><td>Same as maintenance dose</td><td>80 to 240 mg daily in divided doses, orally</td></tr>
| |
| <tr><td>Verampil</td><td>I B</td><td>Same as maintenance dose</td><td>120 to 360 mg daily in divided doses; slow release available, orally</td></tr>
| |
| <tr><td>Diltiazem</td><td>I B</td><td>Same as maintenance dose</td><td>120 to 360 mg daily in divided doses; slow release available, orally</td></tr>
| |
| <tr><th>Heart Rate Control in patients with heart failure and without accessory pathway</th></tr>
| |
| <tr><td>Digoxin </td><td>I C</td><td>0.5 mg by mouth daily</td><td>0.125 to 0.375 mg daily, orally</td></tr>
| |
| <tr><td>Amiodarone</td><td>IIb C</td><td>800 mg daily for 1 wk, orally <br> 600 mg daily for 1 wk, orally <br> 400 mg daily for 4 to 6 wk, orally</td><td>200 mg daily, orally</td></tr>
| |
| </table>
| |
| | |
| * Dabigatran may be used as an alternative to warfarin in those wdo don't have: (I B)
| |
| :* Prosthetic heart valve
| |
| :* Hemodynamically significant valve disease
| |
| :* Severe renal failure (creatinine clearance <15 mL/min) or
| |
| :* Advanced liver disease (impaired baseline clotting function).
| |
| | |
| * If patient on anticoagulants with AF sustains stroke or systemic embolism, target INR may be raised to 3.0 - 3.5 (IIb C).
| |
| * Anticoagulation therapy can be interrupted for upto 1 week, if patients needs a procedure that carries a risk of bleeding (IIa C). For periods > 1 week unfractionated or low molecular weight heparin may be given IV (IIb C).
| |